BB Biotech AGBION:SWX

161.00
1.50 / 0.92%
6.31k
29.11%
1.10
Latest price in CHFToday's changeShares traded1 year changeBeta
Data delayed at least 30 minutes, as of Jul 25 2014 11:46 BST.

Summary

As of last trade BB Biotech AG (BION:SWX) traded at 161.00, 10.56% below its 52-week high of 180.00, set on Feb 26, 2014.

52-week range
Today
118.20
Aug 28 2013
180.00
Feb 26 2014
Markit short selling activity
Low
Medium
High
Open162.30
Day high162.30
Day low160.80
Bid161.00
Offer161.20
Previous close162.50
Average volume14.91k
Shares outstanding11.85m
Free float11.52m
P/E (TTM)2.65
Market cap1.93bn CHF
EPS (TTM)61.40 CHF
Annual div (TTM)4.55 CHF
Annual div yield (TTM)2.80%
Div ex-dateMar 21 2014
Div pay-dateMar 26 2014
Data delayed at least 30 minutes, as of Jul 25 2014 11:46 BST.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
BB Biotech AG+4.48%+3.07%+4.48%+29.11%+125.96%
ALL SHARE CH X INDEX+0.97%+0.37%+5.57%+11.28%+48.03%
Data delayed at least 30 minutes, as of Jul 25 2014 11:46 BST.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.